Unigene Laboratories Inc. reported earnings results for the first quarter ended March 31, 2008. Revenue for the three months ended March 31, 2008 was $4,314,000, compared to $6,328,000 for the three months ended March 31, 2007. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,791,000 for the three months ended March 31, 2008, and $4,461,000 for the three months ended March 31, 2007. Net loss for the three months ended March 31, 2008 was $1,853,000, or $0.02 per share, compared to a net loss of $244,000, or $0.00 per share, for the three months ended March 31, 2007.

Unigene Laboratories Inc., Q1 2008 Earnings/Operating Results Call, May-13-2008

The U.S. Food and Drug Administration (FDA) has approved the use of a new clone for the manufacture of calcitonin, the active ingredient in Fortical(R), Unigene Laboratories Inc.´s nasal spray product for the treatment of osteoporosis. This is the second improvement to the production process approved by the FDA this year. The combination of these improvements is expected to increase batch yields of the product by a factor of three.